SEC Comment Letter for Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Aug 6, 2012
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: Aug. 6, 2012 · CIK: 0001540159 · Accession: 0000000000-12-042223
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-54598
Letter
August 6, 2012 Via E -Mail Mr. Frank Oates President and Chief Executive Officer Stellar Biotechnologies, Inc. 332 E. Scott Street Port Hueneme, California 93041
Re: Stellar Biotechnologies, Inc. Registration Statement on Form 20 -F Filed February 3, 2012 File No. 000-54598
Dear Mr. Oates :
We have completed our review of your filing and related amendments . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing s and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal secur ities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan
Show Raw Text
August 6, 2012 Via E -Mail Mr. Frank Oates President and Chief Executive Officer Stellar Biotechnologies, Inc. 332 E. Scott Street Port Hueneme, California 93041 Re: Stellar Biotechnologies, Inc. Registration Statement on Form 20 -F Filed February 3, 2012 File No. 000-54598 Dear Mr. Oates : We have completed our review of your filing and related amendments . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing s and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal secur ities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan Daniel Greenspan Legal Branch Chief